iBio, Inc. Files 8-K Report
Ticker: IBIO · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1420720
| Field | Detail |
|---|---|
| Company | Ibio, Inc. (IBIO) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing
TL;DR
iBio filed an 8-K on 6/17/25 - standard update.
AI Summary
On June 17, 2025, iBio, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as iBioPharma, Inc., is incorporated in Delaware and headquartered in New York, NY.
Why It Matters
This filing provides an update on iBio, Inc.'s corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K report, which typically contains standard corporate information and does not indicate any unusual or significant events.
Key Numbers
- 001-35023 — Commission File Number (Identifies the company's filing with the SEC)
- 26-2797813 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- iBio, Inc. (company) — Registrant
- June 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York, NY (location) — Business address
- iBioPharma, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 17, 2025.
What is iBio, Inc.'s state of incorporation?
iBio, Inc. is incorporated in Delaware.
What was iBio, Inc.'s former company name?
iBio, Inc.'s former company name was iBioPharma, Inc.
What is the principal executive office address for iBio, Inc.?
The principal executive office is located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 17, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding iBio, Inc. (IBIO).